Head And Neck Cancer
A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug ToxicitiesSeptember 14, 2018
In a small group of head and neck cancer patients, biweekly doses of cetuximab in the maintenance setting appeared to be more tolerable than weekly doses.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
The biomarker may be a predictor of response to treatment and cancer progression in nasopharyngeal carcinoma.
Previous studies have demonstrated that patients with head and neck cancer experience high levels of stress, anxiety, and psychosocial distress throughout the course of the disease.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
Only a few studies have investigated the effectiveness of pazopanib and cetuximab, an angiogenesis inhibitor and EGFR inhibitor, respectively, for head and neck squamous cell carcinoma.
The anti-programmed death 1 (PD-1) antibody pembrolizumab was determined to be an effective second-line option for patients with head and neck cancers.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
Motolimod Combination Therapy Does Not Improve Survival in Squamous Cell Carcinoma of the Head and NeckJune 27, 2018
Previous studies have demonstrated that motolimod can induce positive immune responses, but it did not improve outcomes in the first-line setting in squamous cell carcinoma of the head and neck in the featured study.
New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage DiagnosisJune 19, 2018
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for InhibitionJune 18, 2018
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHNJune 03, 2018
Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
When variables such as age and serious medical conditions were accounted for cancer versus non-cancer mortality was two times higher for women compared with men.
Immune-Related Adverse Events During Anti-PD-1 Therapy May Increase Survival in Head and Neck CancerJune 02, 2018
It is believed that immune competence may modify anti-tumor response with anti-PD-1 therapy.
Two year treatment with pembrolizumab prolonged overall survival compared with standard of care among patients with HNSCC, but the effects on quality of life require further elucidation.
Researchers sought to determine if the addition of nivolumab to radiotherapy and chemotherapy could improve outcomes among this patient population.
Although the addition of stereotactic body radiation therapy (SBRT) to nivolumab did not increase toxicity, it did not lead to any improvement in response rates or survival outcomes among patients with metastatic head and neck squamous cell carcinoma (HNSCC).
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
The CYCORE system may enable physicians to intervene at the early signs of dehydration and other radiotherapy-associated symptoms.
View detailed treatment regimens for head and neck cancers, with options such as cisplatin, cisplatin + radiotherapy, and more.
Oesophagogastro duodenoscopy is a diagnostic procedure to diagnose esophagogastric cancer, but is highly invasive and expensive.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
The total morphine equivalents used were, however, not significantly different between arms.
These findings were, however, significant only in states that expanded Medicaid eligibility.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML
- Later-Line Treatments for Metastatic Urothelial Carcinoma of the Bladder